Meanwhile, lenalidomide was found to have inhibiting function of tumor growth through PI3K/Akt pathway, cereblon/p21, cyclin D1/p27 and Bcl-2 in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) in pre-clinical experiments [9–13]. This evidence concerns the gene CRBN and B-cell chronic lymphocytic leukemia.